Market Overview

VIVUS Initiates Qsymia Get Started! Free Trial Offer Program

VIVUS (NASDAQ: VVUS) initiated the QsymiaTM Get Started! Free Trial Offer Program. The Company is offering eligible patients a Free Trial Offer on a valid prescription for up to a 14 capsule quantity of the Qsymia Starting Dose, 3.75 mg/23 mg (phentermine and topiramate extended-release). Eligible patients are able to receive up to 14 capsules of Qsymia Starting Dose free, including standard shipping and handling charges.

For a patient to qualify for the Get Started! Free Trial Offer Program, they must meet the following eligibility criteria: reside in one of the 50 states, Puerto Rico, Virgin Islands, or Guam and be 18 years or older. This offer is not insurance and is not valid for prescriptions purchased under Medicaid, Medicare or similar federal or state programs or for patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. This offer is not valid where prohibited by law, taxed or restricted, and this offer is limited to one per patient for the duration of the program.

This program is only available through CVS mail order and Walgreens mail order pharmacies that are part of the Qsymia Home Delivery Network. Healthcare providers and patients will be notified of this program through several communication routes, including being prominently displayed on Qsymia.com.

Posted-In: News Pre-Market Outlook Movers

 

Related Articles (VVUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters